Facebook Twitter Instagram Linkedin

Will Remdesivir be the solution for the new coronavirus outbreak (2019-nCoV)?

RemdesivirRemdesivir, GS-5734, C27H35N6O8P molecule. It is antiviral drug for treatment Ebola virus, under study as treatment for Coronavirus 2019-nCoV. Sheet of paper in a cage.Vector illustration

The NIH just published data showing remdesivir prevented disease from coronavirus MERS-CoV when administered before infection and improved the condition of macaques when given after the animals already were infected. (https://lnkd.in/eW5kQfE). MERS-CoV is closely related to the 2019 novel coronavirus (2019-nCoV) but has a higher mortality rate. Researchers have been searching for an antiviral since the infection first appeared in the middle east in 2012. According to the lead author, Emmie de Wit, Ph.D., “Middle East Respiratory Syndrome, caused by the MERS coronavirus (MERS-CoV), continues to cause severe respiratory disease with a high case fatality rate. To date, potential antiviral treatments for MERS-CoV have shown limited efficacy in animal studies. Here, we tested the efficacy of the broad-acting antiviral remdesivir in the rhesus macaque model of MERS-CoV infection. Remdesivir reduced the severity of disease, virus replication, and damage to the lungs when administered either before or after animals were infected with MERS-CoV.”